1.The effects of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Wooksun CHOI ; Jung Yeon SHIN ; Byung Min CHOI ; Kee Hwan YOO ; Baik Lin EUN ; Young Sook HONG ; Joo Won LEE
Korean Journal of Pediatrics 2006;49(12):1315-1323
PURPOSE: This study was conducted to compare the efficacy and safety of ibuprofen and indomethacin in the treatment of patent ductus arteriosus (PDA) in preterm infants and to determine whether ibuprofen can be an alternative drug. METHODS: A total of 32 preterm infants with symptomatic PDA were enrolled in the study. Twelve infants received intravenous ibuprofen 10 mg/kg, followed by 5 mg/kg after 24 and 48 hours. As a comparative group, twenty premature infants received three doses of indomethacin 0.1-0.2 mg/kg every 12 hours. RESULTS: PDA was closed in 11 of 12 infants of the ibuprofen group (92 percent) and in 18 of 20 infants of the indomethacin group (90 percent). Serum sodium concentration decreased along with time significantly (P<0.0001) and to its lowest level at 48 hours after administration of the third dose (P=0.0011) in both groups, but showed no significant difference between two groups. Serum BUN and creatinine concentrations were not changed significantly before or after treatment in each group and showed no difference between thetwo groups. The amount of urine output did not change along with time significantly in both groups (P=0.0725), and showed no significant difference between two groups. CONCLUSION: Ibuprofen has similar effects to indomethacin in the rate of PDA closure and complication when compared. It has similar changes in serum sodium level and complications when compared to indomethacin for the treatment of PDA in preterm infants. Therefore, intravenous ibuprofen may be used as an alternative agent in the treatment of symptomatic PDA in preterm infants.
Creatinine
;
Ductus Arteriosus, Patent*
;
Humans
;
Ibuprofen*
;
Indomethacin*
;
Infant
;
Infant, Newborn
;
Infant, Premature*
;
Sodium
2.Functional recovery after transplantation of mouse bone marrow-derived mesenchymal stem cells for hypoxic-ischemic brain injury in immature rats.
Wooksun CHOI ; Hye Kyung SHIN ; So Hee EUN ; Hoon Chul KANG ; Sung Won PARK ; Kee Hwan YOO ; Young Sook HONG ; Joo Won LEE ; Baik Lin EUN
Korean Journal of Pediatrics 2009;52(7):824-831
PURPOSE: We aimed to investigate the efficacy of and functional recovery after intracerebral transplantation of different doses of mouse mesenchymal stem cells (mMSCs) in immature rat brain with hypoxic-ischemic encephalopathy (HIE). METHODS: Postnatal 7-days-old Sprague-Dawley rats, which had undergone unilateral HI operation, were given stereotaxic intracerebral injections of either vehicle or mMSCs and then tested for locomotory activity in the 2nd, 4th, 6th, and 8th week of the stem cell injection. In the 8th week, Morris water maze test was performed to evaluate the learning and memory dysfunction for a week. RESULTS: In the open field test, no differences were observed in the total distance/the total duration (F=0.412, P=0.745) among the 4 study groups. In the invisible-platform Morris water maze test, significant differences were observed in escape latency (F=380.319, P<0.01) among the 4 groups. The escape latency in the control group significantly differed from that in the high-dose mMSC and/or sham group on training days 2-5 (Scheffe's test, P<0.05) and became prominent with time progression (F=6.034, P<0.01). In spatial probe trial and visible-platform Morris water maze test, no significant improvement was observed in the rats that had undergone transplantation. CONCLUSION: Although the rats that received a high dose of mMSCs showed significant recovery in the learning-related behavioral test only, our data support that mMSCs may be used as a valuable source to improve outcome in HIE. Further study is necessary to identify the optimal dose that shows maximal efficacy for HIE treatment.
Animals
;
Brain
;
Brain Injuries
;
Brain Ischemia
;
Humans
;
Hypoxia-Ischemia, Brain
;
Infant, Newborn
;
Learning
;
Memory
;
Mesenchymal Stromal Cells
;
Methionine
;
Mice
;
Rats
;
Rats, Sprague-Dawley
;
Salicylamides
;
Stem Cells
;
Sulfonium Compounds
;
Transplants
;
United Nations
3.Efficacy and safety of oxcarbazepine in epileptic children.
Hye Kyung SHIN ; Yoon LEE ; Jee Yeon LEE ; Wooksun CHOI ; So Hee EUN ; Baik Lin EUN ; Young Sook HONG ; Joo Won LEE
Korean Journal of Pediatrics 2008;51(2):162-169
PURPOSE: Oxcabarzepine (OXC), newly recommended antiepileptic drug, has been prescribed for patients with partial seizures and generalized tonic clonic seizures in Korea from 1999. There are limited reports about an efficacy of OXC therapy in epileptic children in Korea. This study evaluated the efficacy and safety of OXC in the light of our experience. METHODS: The patients, who had visited the pediatric neurology clinic of Korea University Guro Hospital from January 2001 to December 2006, were included. The data of 144 patients who were administrated OXC as monotherapy or polytherapy, was summarized retrospectively and we evaluated the efficacy and safety of OXC. RESULTS: After 6 months of OXC therapy, 77 patients (53.5%, n=144) achieved seizure freedom, 48 patients (33.3%) experienced >50% improvement. After 12 months of OXC therapy, cessation of seizure was observed in 88 patients (61.1%, n=133), and 27 patients (18.8%) manifested an improvement. Monotherapy group showed superior efficacy to polytherapy one. The frequent side effects of OXC were drowsiness (20.1%), headache (12.5%), dizziness (9.7%) and rash (8.3%). They did not related to patient's age or sex, and dosage of OXC. Twenty four patients (16.7%) experienced hyponatremia, but which were neither symptomatic nor significant one. CONCLUSION: The efficacy and safety of OXC in our patients were excellent and had less significant side effects than established international one. We expect this report contributes toward OXC therapy in epileptic children.
Carbamazepine
;
Child
;
Dizziness
;
Exanthema
;
Freedom
;
Headache
;
Humans
;
Hyponatremia
;
Korea
;
Light
;
Neurology
;
Retrospective Studies
;
Seizures
;
Sleep Stages